|
City Of Hope Selects TrialMaster To Support Clinical Trials
OmniComm Systems, Inc. to deploy a Technology Transfer of the TrialMasterTM
electronic data capture (EDC) solution for clinical data collection
FT. LAUDERDALE, FL - July 11, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC
Bulletin Board: OMCM), one of the fastest growing companies in the Electronic Data
Capture (EDC) marketplace, today announced that City of Hope has selected OmniComm's
EDC solution, TrialMaster and has entered into negotiations on the contract to support
its clinical trials, including Principal Investigator initiated and federally funded
trials. City of Hope also plans to utilize the OmniComm solution to provide EDC
capabilities for the California Cancer Consortium which is comprised of City of
Hope, UC Davis Cancer Center, University of Southern California/Norris Comprehensive
Cancer Center, University of Pittsburgh Cancer Institute and affiliated sites. OmniComm
also announced that it will work with City of Hope to establish an annual Users
Group meeting to be held at the City of Hope campus in Duarte, California.
"OmniComm is truly honored to be chosen as the first line EDC solution by City of
Hope," said Cornelis F. Wit, CEO of OmniComm. "Our consulting services team looks
forward to delivering superior support and training services to City of Hope as
they transition to bring TrialMaster in-house."
"Our extensive experience in conducting oncology trials has uniquely positioned
us to be able to provide the solutions and support that are specific to the operational
environment of the cancer centers," said Stephen Johnson, Sr. VP of Business Development
at OmniComm. "We are looking forward to working in tandem with City of Hope to develop
a library of National Cancer Institute (NCI)-related reusable electronic case report
forms (eCRFs) and to developing product enhancements that will support the full
technology transfer of TrialMaster to City of Hope."
At any given time, City of Hope conducts more than 300 clinical trials encompassing
prevention, screening, treatment, symptom management and quality of life.
Joyce Niland, Ph.D., the Edward and Estelle Alexander Chair in Information Sciences
and Associate Director for Information Sciences at City of Hope Cancer Center, states,
"As an NCI-designated Comprehensive Cancer Center, with a long history of leading
edge research and biomedical informatics development, adopting the OmniComm product
has great potential to further enhance City of Hope's clinical trials enterprise.
We are excited to work with OmniComm to integrate emerging national and international
standards into this product, such as the CDISC Protocol Representation, the BRIDG
information model, and the NCI caBIG modules. We look forward to hosting an interactive
and productive OmniComm User Group on our campus over the coming years."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions
to pharmaceutical, biotechnology, research and medical device organizations that
conduct life changing clinical trial research. OmniComm's growing base of satisfied
customers is a direct result of the company's commitment to deliver products and
services that ensure ease of use, faster study build, ease of integration and better
performance. OmniComm's client intuitive pricing model allows companies that range
from small to mid-size to large scale institutions to safely and efficiently capitalize
on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies
in North America during the last 5 years. In a market overview titled "The Promise
of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given
the highest rating among its competitors for industry middleware. OmniComm Systems
Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn,
Germany, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future
revenues and earnings, plans and objectives for the future operations, future agreements,
future economic performance, operations and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. OmniComm intends that such forward-looking statements be subject to
the Safe Harbors created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm's operations, markets and profitability,
actual results could differ materially and adversely from the expected results.
Back
|
